Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis (STRONGTREAT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Centro per le Malattie Tropicali
European Commission
Information provided by (Responsible Party):
Centro per le Malattie Tropicali Identifier:
First received: March 27, 2012
Last updated: January 20, 2014
Last verified: January 2014

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite.

Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.

Condition Intervention Phase
Drug: Ivermectin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

Resource links provided by NLM:

Further study details as provided by Centro per le Malattie Tropicali:

Primary Outcome Measures:
  • clearance of strongyloides infection [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Clearance of infection is defined by: negative stool agar/charcoal culture - direct examination of three faecal samples for S. stercoralis AND negative serology or decrease in titer below a defined cutoff

Secondary Outcome Measures:
  • All-cause mortality during the 12 months of follow-up. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Patients with partial response to treatment at T 2 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Patients with adverse reactions [ Time Frame: From Day 1st to Day 5th of treatment and from Day 15th to Day 19th (or 72 hours from treatment completion) ] [ Designated as safety issue: Yes ]
    grade 1 to 5 as defined in detailed protocol

  • Patients with increase in blood ALT over cutoff value [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Patients with decrease in WBC count below cutoff value [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Average difference in blood ALT and WBC count at day 17, compared with baseline [ Time Frame: Day 17 ] [ Designated as safety issue: Yes ]
  • Average difference in blood eosinophil count at T2, compared with baseline [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: March 2013
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ivermectin multiple doses
A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
Drug: Ivermectin
Active Comparator: 1 dose ivermectin
A single 200 mcg/kg dose of ivermectin
Drug: Ivermectin


Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients older than 5 years and weighting > 15 kg
  • Current residence in non-endemic areas
  • Either direct diagnosis of S. stercoralis infection AND positive serology at any titer OR positive serology at "high" titer, irrespective of results of direct tests

Exclusion Criteria:

  • Pregnant or lactating women
  • Subjects suffering from CNS diseases
  • Disseminated strongyloidiasis
  • Immunocompromised patients.
  • Lack of informed consent
  • Previous treatment with ivermectin (in the last year)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01570504

Contact: Dora Buonfrate, MD +39 601 3563

IMTA Not yet recruiting
Antwerp, Belgium
Centro per le Malattie Tropicali, Ospedale Sacro Cuore Recruiting
Negrar, Verona, Italy, 37024
Clinica di Malattie Infettive e Tropicali Recruiting
Brescia, Italy
Unità di Malattie Infettive, Anna Meyer Children's Universisty Hospital Active, not recruiting
Florence, Italy
UFDID, Azienda Ospedaliero-universitaria Careggi Recruiting
Florence, Italy
Reparto Malattie Infettive, Ospedale Ca' Foncello Active, not recruiting
Treviso, Italy
UPCH, Hospital Cayetano Heredia Not yet recruiting
Lima, Peru
Unidad de Medicina, Hospital de Poniente-El Ejido Recruiting
El Ejido, Almeria, Spain
Principal Investigator: Joaquin Salas Coronas         
FCRB, Hospital Clinic de Barcelona Active, not recruiting
Barcelona, Spain
Unitat Medicina Tropical i Salut Internacional Drassanes Not yet recruiting
Barcelona, Spain
United Kingdom
UCLH Active, not recruiting
London, United Kingdom
Sponsors and Collaborators
Centro per le Malattie Tropicali
European Commission
  More Information

No publications provided

Responsible Party: Centro per le Malattie Tropicali Identifier: NCT01570504     History of Changes
Other Study ID Numbers: CTD1-2012, 2011-002784-24
Study First Received: March 27, 2012
Last Updated: January 20, 2014
Health Authority: Italy: Ethics Committee

Keywords provided by Centro per le Malattie Tropicali:
Strongyloides stercoralis

Additional relevant MeSH terms:
Rhabditida Infections
Secernentea Infections
Nematode Infections
Parasitic Diseases
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions processed this record on October 19, 2014